Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile  and contains information from public web pages.

Prof. Kaj Blennow

Wrong Prof. Kaj Blennow?


84 Total References
Web References
Kaj ..., 5 Nov 2012 [cached]
Kaj Blennow
Kaj Blennow
Kaj Blennow is head of the research team on "Neurochemical Pathogenesis and Diagnostics" at the Dept. of Clinical Neuroscience, University of Gothenburg, Sweden. His major research interests are studies on ...
Comment on Kaj Blennow
Alzheimer's Association Partnerships | Biomarker Projects, 10 Mar 2012 [cached]
To address these issues, Kaj Blennow, M.D., Professor of Clinical Neurochemistry at the University of Gothenburg (Sweden), drafted a survey to be completed by European AD investigators engaged in CSF assays for AD research or practice. Dr. Blennow invited representatives from Washington University, St Louis, to develop the survey further and introduce it to the Alzheimer's Disease Centers (ADCs).
"This study provides support that ..., 24 April 2012 [cached]
"This study provides support that anti-amyloid immunotherapy may affect the degenerative process in AD," Kaj Blennow, M.D., Ph.D., of the clinical neurochemistry laboratory, University of Gothenburg, said in an interview with Medscape Medical News.
"This is one of the most ..., 12 Nov 2012 [cached]
"This is one of the most important pieces of direct evidence that individual persons have the disease and all the pathology many years before," said Dr. Kaj Blennow, a professor in clinical neurochemistry at the University of Gothenburg in Sweden, who was not involved in the research.
Dr. Blennow said that while researchers know that amyloid plaques plateau when people already have dementia, they did not know that the plateau appears to occur years before.
Cerebrospinal Fluid Shows Alzheimer's Disease Deterioration Much Earlier, 19 June 2009 [cached]
The disease is one that progresses slowly, and the pharmaceuticals that are currently available are only able to alleviate the symptoms," says Kaj Blennow, professor at the Sahlgrenska Academy, and a world-leading researcher in the field. Several biomarkers have been identified in recent years. Biomarkers are proteins that can be detected in the cerebrospinal fluid and used to diagnose Alzheimer's disease. It is now clear that the typical pattern of biomarkers known as the "CSF AD profile" can be seen in the cerebrospinal fluid of patients even with very mild memory deficiencies, before these can be detected by other tests.
"The patients who had the typical changes in biomarker profile of the cerebrospinal fluid had a risk of deterioration that was 27 times higher than the control group. We could also see that all patients with mild cognitive impairment who deteriorated and developed Alzheimer's disease had these changes in the biomarker profile of their cerebrospinal fluid," says Kaj Blennow.
Other People with the name "Blennow":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.